Table of Contents Table of Contents
Previous Page  135 / 328 Next Page
Information
Show Menu
Previous Page 135 / 328 Next Page
Page Background

AOAC RESEARCH INSTITUTE 

Expert Review Panel Chair Report for Veterinary Drug Residues – Dyes in Seafood  

Page 5 of 6 

MEETING MINUTES 

I.

Welcome and Introductions 

The Expert Review Panel Chair, Dr. Joe Boison of the Canadian Food Inspection Agency (CFIA) members, and 

discussed the goal of the meeting.     

II.

Review of AOAC Volunteer Policies & Expert Review Panel Process Overview and Guidelines

Deborah McKenzie presented a brief overview of AOAC Volunteer Policies, Volunteer Acceptance 

Agreement and Expert Review Panel Policies and Procedures which included Volunteer Conflicts of Interest, 

Policy on the Use of the Association, Name, Initials, Identifying Insignia, Letterhead, and Business Cards, 

Antitrust Policy Statement and Guidelines, and the Volunteer Acceptance Form (VAF).  All members of the 

ERP were required to submit and sign the Volunteer Acceptance Form.  In addition, she also presented an 

overview of the ERP process including meeting logistics, consensus, First Action to Final Action 

requirements, and documentation. 

III.

Discuss Final Action Requirements for First Action Official Methods

All ERP members presented a review and discussed the information received from the method author for the 

AOAC First Action method AOAC 2012.25:  Three Triphenylmethane Dyes Residues and Their Metabolites 

(Malachite Green, Leuco Malachite Green, Crystal Violet, Leuco Crystal Violet, Brilliant Green) In Aquaculture 

Product, LC‐MS/MS, First Action 2012

,

which has approached the 2‐year tracking period.

The method 

authors, Wendy Andersen of United States Food and Drug Administration, and Eric Verdon of ANSES ‐ 

French Agency for Food, Environmental and Occupational Health & Safety, were present and able to address 

the questions and concerns of the ERP.  A summary of comments was provided to the ERP and the method 

authors.

2

  The ERP is required to make a recommendation on AOAC Official First Action methods, 2 years 

after adoption, to the AOAC Official Methods Board regarding Final Action status.  By consensus the ERP 

presented the following motions for AOAC 2012.25

:

Motion by An; Second by Martos,

 to recommend to the AOAC Official Methods Board, First Action 

Method AOAC 2012.25 for AOAC Final Action Official Methods status.    

Consensus demonstrated by: 7 in favor, 0 opposed, and 0 abstentions. Unanimous,

Motion Passed.  

The ERP members noted additional discussion items regarding the details of the recommendation for AOAC 

Final Action Official Methods status that will assist in the AOAC Official Methods Board review.   

Strengths, Weakness, and Community Needs 

The method is easy to follow, speedy, flexible, has a broad scope, and can be evaluated amongst 

different matrices that will benefit the community that it serves.  In addition, there are many 

publications available that help support the method.  It was also noted that the method will be 

moving forward as an FDA Regulatory standard due to the data being easily reliable.  

Reference Materials 

The ERP noted that there are currently no reference materials available for these types of drugs and 

may need someone to generate reference materials in the future.  The compounds are declared not 

acceptable for daily intake and cannot be used in fish production.  The ERP should continue to 

monitor for future implementation in regulatory environments.   

2

Attachment 1: Summary of Expert Reviewer Comments for AOAC 2012.25

ERP PROFILE SUMMARIES

112